13F Holdings
中文EN

PULM Pulmatrix, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%

Returns

ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$7.81M$7.30M$6.07M$5.17M
R&D expense$38,000$7.17M$15.52M$18.24M$15.38M
SG&A expense$5.13M$7.79M$6.52M$6.78M$6.38M
Operating income-$5.17M-$9.76M-$14.74M-$18.95M-$20.17M
Income tax$0————
Net income-$5.16M-$9.56M-$14.12M-$18.84M-$20.17M
EBITDA—-$9.66M-$14.61M-$18.79M-$20.00M
EPS (basic)-1.41-2.62-3.87-5.46-8.63
EPS (diluted)-1.41-2.62-3.87-5.46-8.63
Weighted avg. shares (diluted)3.65M3.65M3.65M3.45B2.71M
Banking
Net interest income—$467,000$867,000$309,000$7,000
Balance sheet
Cash & equivalents$4.09M$9.52M$19.17M$35.63M$53.84M
Receivables——$928,000$1.30M$67,000
Current assets$4.13M$9.92M$20.84M$38.15M$54.78M
PP&E, net——$1.16M$235,000$321,000
Total assets$4.14M$9.94M$33.96M$40.95M$58.82M
Current liabilities$329,000$929,000$3.91M$5.02M$4.44M
Total liabilities$329,000$996,000$15.96M$9.84M$11.37M
Shareholders' equity$3.81M$8.95M$18.00M$31.11M$47.45M
Shares outstanding3.65M3.65M3.65M3.64M3.22M
Cash flow statement
Operating cash flow-$5.43M-$10.72M-$15.98M-$19.36M-$19.73M
Capital expenditure—$398,000$676,000$86,000$144,000
Free cash flow—-$11.11M-$16.66M-$19.44M-$19.87M
Investing cash flow—-$398,000-$676,000-$86,000-$144,000
Financing cash flow——$53,000$1.23M$43.48M
Depreciation & amortization—$106,000$134,000$162,000$169,000
Stock-based compensation$25,000$511,000$954,000$1.11M$1.16M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.